**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 10108**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (6): *Helicobacter pylori*

Optimizing clarithromycin-containing therapyfor *Helicobacter pylori* in the era of antibiotic resistance

Molina-Infante J *et al.* Optimizing clarithromycin-based *H.pylori* therapy

Javier Molina-Infante, Javier P Gisbert

**Javier Molina-Infante,** Department of Gastroenterology, Hospital San Pedro de Alcantara, 10003 Caceres, Spain

**Javier P Gisbert**, Department of Gastroenterology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 28006 Madrid, Spain

**Author contributions**: Molina-Infante J and Gisbert JP contributed equally to this work.

**Correspondence to: Javier Molina-Infante, MD,** Department of Gastroenterology, Hospital San Pedro de Alcantara, C/ Pablo Naranjo s/n 10001 Caceres, Spain. xavi\_molina@hotmail.com

**Telephone:** +34-927-621543 **Fax:**+34-927-621543

**Received:** August 25, 2013  **Revised:** March 14, 2014

**Accepted:** April 5, 2014

**Published online:**

**Abstract**

The efficacy of triple therapy for *Helicobacter pylori* infection has dramatically declined over the last decade, largely related to increasing clarithromycin resistance rates. From a microbiological standpoint, bismuth quadruple therapy is the ideal replacement since it combines drugs for which resistance does not impair its efficacy. Nonetheless, several obstacles such as availability, complexity or tolerance prevent a general implementation of bismuth quadruple therapy, so non-bismuth quadruple regimens remain the best first-line treatment in clinical practice in many geographical areas. We review the rationale and efficacy of several optimization tools (increasing the length of duration, high-dose acid suppression, probiotics), which have been largely evaluated over the last 5 years to increase the effectiveness of standard triple therapy. Then, we update available evidence on the effectiveness of several non-bismuth quadruple therapies (sequential, concomitant, hybrid, miscellaneous therapy), which have gained interest lately. We also revise evidence on the efficacy of the aforementioned optimization tools for non-bismuth quadruples schemes and, finally we provide a novel regionalized therapeutic algorithm, based on novel formulas recently developed for predicting the outcome of non-bismuth quadruple regimens, upon local antibiotic resistance rates.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Keywords:** *Helicobacter pylori*; Eradication; Clarithromycin; Sequential; Concomitant; Hybrid; Antibiotic resistance; Bismuth

**Core tip:** Triple therapy is no longer effective to eradicate *Helicobacter pylori* infection in most settings across the world. Bismuth quadruple therapy has resurfaced as an ideal replacement, despite its implementation in clinical practice may be troublesome. As such, non-bismuth quadruple therapies remain in the therapeutic front line in clinical practice. This article updates available evidence over the last five years on the efficacy of several non-bismuth quadruple schemes and different tools used to optimize them, providing a novel regionalized therapeutic algorithm, according to novel predicting models based on local antibiotic resistance rates.

Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapyfor *Helicobacter pylori* in the era of antibiotic resistance.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

*Helicobacter pylori (H. pylori)* is a worldwide infection that affects millions of people. This infection is currently the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. It was thirty years ago that *H. pylori* was discovered[1] and twenty years ago that clarithromycin-based triple therapy was established in clinical practice for the eradication of this infection[2]. Nowadays, the efficacy of triple therapy is seriously challenged in many parts of the world, where eradication rates have declined to unacceptably low levels, largely related to development of resistance to clarithromycin[3].

 From a microbiological standpoint, the most rational way to overcome antibiotic resistance would be the use of a combination of drugs for which resistance does not appear to be a problem, so no clarithromycin-based regimens should be recommended in geographical areas with increasing clarithromycin resistance rates. In this context, bismuth-based quadruple therapy seems to be an attractive alternative treat­ment, especially in its most recent galenic formula­tion, bismuth subcitrate potassium, metronidazole, and tetracycline (BMT, sold under licence as Pylera®)[4]. However, this logical scenario is not a realistic approach in many settings for clinical practice owing to a number of obstacles. *H. pylori* infection is mostly diagnosed and treated by gastroenterologists, instead of microbiologists, so the bulk of treatment is prescribed on an empirical basis and articles seldom report data on antibiotic resistance. Furthermore, bismuth salts are not widely available, many countries are currently experiencing a general unavailability of tetracycline and the launch of Pylera®, the three-in-one capsule decreasing pill burden and improving compliance for bismuth quadruple therapy, onto the market is being troublesome as well.

 As such, several non-bismuth quadruple therapies have made a leap towards the front line to tackle *H. pylori* infection. Indeed, a formula has been elegantly developed to predict the outcome of these therapies according to antibiotic resistance rates[5]. The aim of this review is to summarize optimization tools and therapeutic innovations published over the last 5 years (August 2008- August 2013) aimed at increasing the efficacy of *H. pylori* clarithromycin-based first-line therapies.

**OPTIMIZING TRIPLE THERAPY**

***Increasing the length of duration***

It has been postulated that extending the duration of triple therapy up to 14 d might result in higher and acceptable cure rates. In fact, recent European guidelines state that extending the duration of Proton pump inhibitor (PPI)-clarithromycin-containing triple therapies from 7 to 10-14 d improves the eradication success by about 5% and may be considered[6]. Conclusions from reviews and meta-analysis are mostly consistent with showing a clinical benefit of extending the duration[7,8], but other have drawn the opposite conclusion[9]. Similarly, recent articles have disclosed a benefit of prolonging the length of triple therapy in Greece[10] and Croatia[11], whereas others from Korea[12] and Turkey[13] could not demonstrate an advantage for this strategy. As such, prolonging *H. pylori* triple therapy seems to increase eradication rates, albeit whether it represents a clinically useful strategy should be locally evaluated.

***Increasing acid-suppressive therapy***

*H. pylori* typically resides within the mucus layer of the human stomach, being the bulk of organisms attached to surface cells. Most importantly, a proportion of the organisms may remain in a non-replicative but viable state, which notably reduces the effectiveness of antibiotics that require microbial replication to kill the organisms, such as clarithromycin and amoxicillin[3]. This non-replicative state, which turns *H. pylori* phenotypically resistant, is more likely when gastric pH ranges from 3 to 6. Increasing the pH in this layer to 6 or 7 allows the bacteria to enter the replicative state where they become susceptible to amoxicillin and clarithromycin[3]. Therefore, the stronger acid suppression is, the higher the likelihood of antibiotic therapy success.

 PPI therapy (omeprazole, lansoprazole, pantoprazole, , rabeprazole, esomerpazole,) are now widely used as the first-line acid inhibitors in eradication schemes. These drugs undergo hepatic metabolism via the CYP450 pathways and the isoforms CYP2C19 and, to a lesser extent, CYP3A4. There are interindividual differences in the activity of CYP2C19, which may impact PPIs pharmacokinetic behaviour and clinical efficacy[14,15]. Indeed, the phenotype of CYP2C19 is categorized into three groups: extensive or rapid metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM). The rate of CYP2C19 rapid metabolizers was proven to be higher in Europeand in North America (56%–81%), while the proportion was smaller (27%–38%) in the Asianpopulation[16]. Significantly higher eradication rates of *H. pylori* have been observed in patients with poor and intermediate metabolizers phenotype when compared to extensive metabolizers[17]. As such, initial genotyping for this enzyme would be ideal before *H. pylori* therapy, since higher dosage in extensive metabolizers is likely to improve the clinical efficacy of PPIs for *H. pylori* therapy. Seeing as this approach is unrealistic in clinical practice, it is conceivable that all patients, especially in Europe and North America, should receive high-dose PPI therapy to circumvent the high rate of PPI rapid metabolizers.

 As for the different PPI available molecules, a recent meta-analysis disclosed that he efﬁcacy of omeprazole- and lansoprazole- based ﬁrst-line triple therapies at the standard doses was dependent on CYP2C19 genotype status, which appeared not to affect the efﬁcacy of the regimens including rabeprazole[18]. In line with this finding, two other recent meta-analyses have demonstrated that esomeprazole and rabeprazole provide better overall *H. pylori* eradication rates, especially in CYP2C19 extensive metabolizers[19,20].

 Finally, updated European Guidelines for *H. pylori* management have also recommended high-dose PPI therapy using new generation-PPIs, pointing out that increasing the dose of PPI from, for example, 20 mg omeprazole twice daily to 40 mg of esomeprazole or rabeprazole twice daily may increase cure rates by 8%-12%[6].

***Probiotics***

Probiotics are live organisms or produced substances that are orally administrated, usually in addition to conventional antibiotic therapy for *H. pylori* infection. They may modulate the human microbiota, stimulate the immune response and directly compete with pathogenic bacteria, besides preventing antibiotic side effects[21]. Indeed, probiotics have exhibited inhibitory activity against *H. pylori* *in vitro* and *in viv*[22,23]. At the present time, 6 meta-analyses have been published addressing the benefit of *Lactobacillus and Bifidobacterium*[24,25], bovine lactoferrin[26,27], fermented milk-based[28], *Lactobacillus* [29] and *Saccharomyces boulardii* [30] probiotic formulations. The main results of these meta-analyses are summarized in Table 1. Available evidence collectively points towards a benefit of using probiotic for decreasing antibiotic-related side effects and, to a much lesser extent, increasing cure rates.

 However, several considerations should be made before recommending probiotic in clinical practice. To begin with, they add complexity as they mean a fourth or fifth drug, depending on dealing with triple and quadruple therapies, and it may increase the risk of poor compliance with therapy. Furthermore, probiotics are "over-the-counter" medications and the cost of eradication therapy may notably rise. On the other hand, the role of probiotics in children is controversial, as they have shown to decrease antibiotic-related side effects but no impact on eradication rates[31]). In this line, several adult trials have disclosed as well negative results on cure rates for probiotic supplementation[32-34]. Most likely, the discordant results are probably related to the different products used, their different concentrations, probiotic strain, dose and the length of duration. Further studies refining the most effective probiotic and the patient profile which will most benefit from probiotic supplementation are needed before a general recommendation in clinical practice can be made.

***Long-acting drugs***

A recent study from Thailand reported 100% cure rates with 14-day high-dose PPI and long-acting clarithromycin[35]. However, there were no clarithromycin-resistant *H. pylori* strains in the study, so these drugs need further validation in other geographical areas with different patterns of antibiotic resistance. At the present time, no study has evaluated this attractive hypothesis. The use of long-acting macrolides (azithromycin) has been recently associated with increasing *H. pylori* resistante to clarithromycin[36]. Azithromycin is known to achieve high concentrations in the gastric mucus and gastric juice for several weeks after its administration, and this may lead to local subinhibitory concentrations and favour the selection of macrolide-resistant mutants, as above mentioned.

**NON-BISMUTH QUADRUPLE TREATMENTS**

***Sequential therapy***

Sequential therapy was developed in Italy in 2000 as a replacement for triple therapy[37,38]. It consists of 5 d of PPI therapy plus amoxicillin, followed by a further five days of PPI with two other antibiotics, usually clarithromycin and metronidazole. Up to 2008, the vast majority of studies on this therapeutic strategy had been conducted in Italy. In 2007, a randomized controlled trial from the same Italian authors showed a significant advantage of 10-day sequential over 10-day triple therapy (91% *vs* 78%, *P* = 0.002), being highly effective against clarihtromycin-resistant strains[39]. A pooled data analysis with Italian evidence showed promising eradication rates higher than 90%, even in patients with risk factors for triple therapy failure (clarithromycin or metronidazole resistance, non ulcer dyspepsia, smoking or the absence of the gene CagA)[40]. Indeed, several meta-analyses evidenced the advantage of sequential therapy over triple therapy[41-43]. Accordingly, it was suggested in 2007 by the American College of Gastroenterology Guidelines[44] and the European Maaastricht Consensus (Maastricht III)[45], as well as in 2009 by the Second Asia-Pacific Consensus Guidelines[46], that sequential therapy was a promising therapy, but it required further evaluation outside Italy, before a generalized change in first-line *H. pylori* treatment was recommended.

 In 2010, a critical review of the evidence highlighted several concerns in previous meta-analyses, such as lack of validation outside of Italy, low quality studies or insufficient information on the effect on antibiotic resistant strains[47]. In 2011, a large multicenter trial from Latin America showed no advantage of 10-day sequential therapy over 14-day triple therapy[48]. In 2012 and 2013, an updated meta-analysis in children and two systematic reviews in adults dealing with sequential therapy have been published[49-51]. The results are summarized in Table 2. From 2008 to 2012, cure rates of sequential therapy in studies conducted in Asia, Europe and Latin America remained significantly better than those of triple therapy, but mean eradication rates dramatically dropped by 15% (79%-81%) compared to Italian trials before 2008. A recent multicenter study performed in Taiwan comparing 14-day sequential and triple therapy has definitely shown the limitations of sequential therapy[52], since the efficacy of this regimen was impaired by either clarithromycin and metronidazole resistance. Finally, a recent meta-analysis performed by the Italian creators of the sequential therapy[53] showed a mean cure rate of 84% (95%CI: 82.1%-86.4%) for 10-day sequential therapy, being superior to seven day triple therapy, marginally superior to 10 day triple therapy but not superior to 14 day triple therapy. Right now, 10-day sequential therapy cannot be considered a good therapeutic option to overcome antibiotic resistance and its failure might be expected when dual resistant strains are > 5%[7].

The history of sequential therapy is a good one to learn. It was devised in 2000 in response to failure of triple therapy and was systematically compared to an "unfair comparator" (triple therapy), leading to a notable superiority of sequential therapy in meta-analyses. The treatment formula was not optimized and the detrimental effect of claritrhomycin was noted, but not that of metronidazole[7]. It took as a decade to understand microbiological drawbacks of sequential therapy and we cannot afford to trip over the same stone when it comes to evaluating new *H. pylori* therapies.

***Concomitant therapy***

The concept of a “non-bismuth quadruple regimen” or “concomitant” regimen (the term used hereafter) consists of converting standard triple therapy to a quadruple therapy by the addition of 500 mg of metronidazole or tinidazole twice daily. In 1998, two groups of investigators, one in Germany and the other in Japan, proposed that a PPI, amoxicillin, clarithromycin, and nitroimidazole be given concurrently as a four-drug, three-antibiotic, non-bismuth-containing quadruple regimen[54,55]. Despite the short duration of therapy (5 d on average), this approach provided, at that time, high cure rates (90% by intention-to-treat). After a few years of research, it fell into oblivion but resurfaced in 2010 as an alternative therapy to triple and sequential therapy[56]. Since then, eleven studies have evaluated its effectiveness in Latin America[48], Asia (Thailand[57], Japan[60], Taiwan[61], China[63], South Korea[58,69]) and Europe (Spain[62,65,67], Greece[64,66], Italy[59,67] and Turkey[68]). The results are disclosed in Figure 1, broken down by the lenght of therapy. Regardless of the duration of therapy, all studies showed intention-to-treat cure rates from 85% to 94%, with 4 exceptions (2 studies with a 5-day duration from Latin America (73.5%)[56] and Korea (80.7%)[58], and 2 studies with a 14-day duration from Turkey (75%)[68] and South Korea (80.8%)[69].

 In the aforementioned article by Graham *et al*[7], the efficacy of 14-day concomitant therapy was not impaired by neither clarithromycin nor metronidazole isolated resistance, but it is expected to fall below 90% when the prevalence of dual clarithromycin-metronidazole resistant strains is > 15%. Therefore, the authors state that it cannot be recommended in settings where metronidazole resistance is greater than 60% (*i.e*., China, India, Iran or Central or South America) or in populations at high risk of dual resistance (*i.e.*, following claritrhomycin or metronidazole treatment failures). These recommendations are in agreement with suboptimal results in Latin America[56], South Korea[58,69] and Turkey[68], where clarithromycin, but specially metronidazole, resistant *H. pylori* strains are very prevalent. Likewise, they match with good to excellent results in Southern Europe and some Asian countries, where claritrhromycin ranges from low (9%) to high (40%) figures, but metronidazole resistance remains in relatively low figures (< 30%-40%).

***Sequential or concomitant therapy?***

Several studies have lately evaluated the efficacy of sequential and concomitant non-bismuth quadruple therapies against clarithromycin and metronidazole resistant strains. Georgopoulos *et al*[71] nicely addressed this issue and we have adapted their results to exhibit the most recent evidence (Table 3). Concomitant and sequential therapies were succesful against dual-resistant strains in 78% (18/23) and 33% (9/27) of the cases, respectively. Furthermore, a recent meta-analysis[72] comparing sequential and concomitant therapy has shown a significant adavantage (OR *=* 1.51; 95%CI: 1.06-2.17) of concomitant therapy (Figure 2). Overall, solid evidence point towards concomitant therapy being a more reasonable therapeutic option in areas with a high incidence of clarithromycin and/or metronidazole resistance[71], even though we cannot miss the fact that it is expected to fail when the prevalence of dual clarithromycin-metronidazole resistant strains is > 15%[7].

***Hybrid therapy: a new kid on the block***

Hybrid sequential-concomitant regimen is a therapeutic innovation which includes a proton pump inhibitor (PPI) plus amoxicillin for 14 d, adding clarithromycin and a nitroimidazole for the final 7 d. In other words, it is a 7-day first dual phase (PPI + amoxicillin) followed by a 7-day quadruple phase (PPI + amoxicillin + clarithromcyin + nitroimidazole). In 2011, a pilot study revealed outstanding cure rates [97% intention-to-treat (ITT) analysis] in three Taiwanese centers[73]. However, the rate of clarithromycin resistance in this region is low (7%) and required further validation in setting with different patterns of reistance. In 2012, hybrid therapy demonstrated to achieve significantly higher ITT cure rates over sequential therapy (89.5% *vs* 76.7%, p 0.001) in Iran[74], a setting with high rates of antibiotic resistance. More recently, a noninferiority trial conducted in Spain and Italy[67] showed that both optimized concomitant and hybrid therapy achieved ITT eradication rates > 90% in settings with high rates of clarithromycin and metronidazole resistance. In this trial, hybrid therapy led to successful eradication in 1 out of 3 (33%) dual resistant strains. These are preliminary small numbers and definitely further research is warranted on this matter. Finally, a pilot study conducted in Italy[59] compared 5-day concomitant therapy, 10-day sequential therapy and 14-day hybrid therapy. Surprisingly, 5-day concomitant and 10-day sequential therapy achieved acceptable cure rates (> 90% on PP analysis), but not hybrid therapy (80%).

**CAN WE OPTIMIZE NON BISMUTH QUADRUPLE REGIMENS?**

***Duration of therapy***

As for sequential therapy, 10-day sequential therapy was not superior to 14 day triple therapy, but 14-day sequential therapy proved to be superior to 14-day triple therapy[7,52,53]. Furthermore, metronidazole resistance undermines 10-day sequential therapy at 20% and 14-day sequential therapy at 30%[7].

 Regarding concomitant therapy, meta-analyses have shown that the outcome is duration dependent[75,76]. In a recent head-to-head comparison in Thailand[57], 5-day proved unsatisfactory compared to 10-day concomitant therapy, besides 5-day concomitant therapy has also shown its failure in Latin America[48] and South Korea[58]. In the authors´ experience, 14-day concomitant[67] achieved the best ITT results (92%) compared to studies evaluating 10-day concomitant therapy(86%-87%)[62,65].

***Acid suppression***

Both triple therapy and non-bismuth quadruple therapy contain amoxicillin and clarithromycin. As such, it is conceivable to speculate that the above mentioned data are valid for both therapies. Further studies are warranted to elucidate whether high-dose PPI therapy and either esomeprazole or rabeprazole show superiority for non-bismuth quadruple regimens (as it has been the case with triple therapy).

***Probiotics***

At the present time, data on the usefulness of probiotics for *H. pylori* eradication with quadruple therapies is anecdotical. Two recent trials[77,78] showed a reduction of side effects of probiotics combined with bismuth quadruple therapy and sequential therapy, but no increase in cure rates. No study has evaluated the addition of probiotics to concomitant or hybrid therapy.

 Optimization of non-bismuth quadruple therapies (increasing antibiotic burden or increasin length of duration) adds complexity and might impact negatively on compliance with therapy. Regardless of the effect on cure rates, probiotics might be important to improve tolerance and compliance. On the contrary, they are "over-the-counter" drugs, therefore increasing costs, and add a fifth drug and may as well add complexity. More studies are required to refine the role of probiotics for these therapies and depict the patient characteristic that would benefit from coadyuvant probiotic supplementation.

**MISCELLANEOUS THERAPY: THE SUPER-OPTIMIZATION**

Recently, an interesting pilot study from Colombia evaluating a “super-optimized” therapy, so called "miscellaneous", has been published[79]. It consists of high-dose metronidazole (500 t.d.s) all along the therapy (15 d), dividing the remaining drugs in three 5-day phases: (1) First 5 d (lansoprazole 30 mg *bid* and amoxicillin 1 g *bid*); (2) Days 6 to 10: lansoprazole 30 mg *qds*; and (3) Days 11 to 15: lansoprazole 30 mg *bid* and clarithromycin 500 mg *bid*.

 Therefore, this quadruple therapy has an optimized duration (15 d), high-dose PPI, high-dose metronidazole during 15 d trying to overcome the high rate of resistance (> 70%-80%) in Latin America and, of note, has a halfway period in which acid suppression is optimized (lansoprazole 120 mg/d) in order to avoid selection of non-replicative *H. pylori* strains. In this pilot study, miscellaneous therapy led to successful eradication rates [94% and 91% by per protocol (PP) and ITT, respectively], with a high rate of full compliants (96%) and acceptable side effects rate (55%), all of them mild.

 Miscellaneous therapy is obviously burdened by its complexity and maybe its cost, depending on the geographical location, but provides an interesting and effective therapeutic tool in settings with metronidazole resistance > 40%, in which theoretically Maastricht IV precludes using metronidazole[6]. Definitely, more studies are awaited in this line of work to overcome antibiotic resistance.

**THERAPEUTIC ALGORITHM**

Following this review, we propose a modified therapeutic algorithm for first-line *H. pylori* therapy (Figure 3). The success of treatments for infectious diseases is predictable if one knows the pattern of resistance and the effect of resistance on the regimens tested[7]. Clarithromycin resistance was the Achiles heel for triple therapy and now dual clarithromycin resistance rates is the Achiles heel for non-bismuth quadruple therapies. Non-bismuth sequential, hybrid and concomitant therapies are expected to fail if the rate of dual-resistant strains are > 5%, > 9% and > 15%, respectively. As such, eradication therapy should be “regionalized” depending on the prevalence of clarithomycin and metronidazole resistant strains. Currently, triple therapy should only be acceptable if eradication rates > 90% have been documented.

**TAKE-HOME MESSAGES**

***Optimization tools for triple therapy***

(1) Prolonging *H. pylori* triple therapy up to 14 d increases eradication rates by approximately 5%, albeit the clinical benefit of this strategy should be evaluated locally; (2) High-dose PPI therapy is recommended for triple therapy, especially in Europe and North America, where the prevalence of PPI extensive metabolizers is higher; (3) A discrete advantage of esomeprazole and rabeprazole over omeprazole, pantoprazole and lansoprazole has been shown in recent meta-analyses; and (4) Overall, probiotics seem to increase eradication rates and reduce antibiotic side-effects in adults, but they cannot be recommended for clinical practice yet.

***Sequential therapy***

Updated data in both children and adults point towards lower eradication rates than previously reported. Despite sequential therapy keeps on showing an advantage over triple therapy, unacceptable cure rates have been recently reported, without a therapeutic advantage over 14-day triple therapy. Its efficacy dramatically decreases upon the existence of metronidazole and dual clarithromycin and metronidazole resistant strains.

***Concomitant therapy***

Emerging evidence has shown concomitant therapy to be an effective therapy (> 90% cure rates) in Southern Europe and some Asian countries (Thailand, Taiwan, Japan, China). Compared to sequential therapy, its efficacy is less impaired by clarithromycin and metronidazole resistant strains and therefore seems to be the best replacement for triple therapy. However, it has been proven unsuccessful in Turkey and South Korea, where both clarithromycin and specially metronidazole, resistance rates are notably high.

***Hybrid therapy***

It is a therapeutic innovation combining sequential and concomitant therapy, with a 7-day first dual phase (PPI + amoxicillin) followed by a 7-day quadruple phase (PPI + amoxicillin + clarithromcyin + nitroimidazole). It has currently demonstrated an advantage over sequential therapy and not to be inferior to concomitant therapy, although further research is warranted.

**REFERENCES**

1 **Marshall BJ**, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; **1**: 1311-1315 [PMID: 6145023 DOI: 10.1016/S0140-6736(84)91816-6]

2 **Bazzoli F**, Zagari RM, Fossi S, Pozzato P, Roda A, Roda E. Efficacy and tolerability of a short-term low-dose triple therapy for eradication of Helicobacter pylori. *Gastroenterology* 1993; **104**: 40A (Abstract).

3 **Graham DY**, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. *Gut* 2010; **59**: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]

4 **Mégraud F**. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. *Therap Adv Gastroenterol* 2012; **5**: 103-109 [PMID: 22423259 DOI: 10.1177/1756283X11432492]

5 **Graham DY**, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. *Clin Gastroenterol Hepatol* 2014; **12**: 177-86.e3; Discussion e12-3 [PMID: 23751282 DOI: 10.1016/j.cgh.2013.05.028]

6 **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

7 **Calvet X**, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. *Aliment Pharmacol Ther* 2000; **14**: 603-609 [PMID: 10792124]

8 **Ford A**, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? *Can J Gastroenterol* 2003; **17** Suppl B: 36B-40B [PMID: 12845349]

9 **Fuccio L**, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. *Ann Intern Med* 2007; **147**: 553-562 [PMID: 17938394]

10 **Karatapanis S**, Georgopoulos SD, Papastergiou V, Skorda L, Papantoniou N, Lisgos P, Kouvidou C, Fragkou P, Mentis A. "7, 10 and 14-days rabeprazole-based standard triple therapies for H. pylori eradication: are they still effective? A randomized trial". *Acta Gastroenterol Belg* 2011; **74**: 407-412 [PMID: 22103045]

11 **Filipec Kanizaj T**, Katicic M, Skurla B, Ticak M, Plecko V, Kalenic S. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens. *Helicobacter* 2009; **14**: 29-35 [PMID: 19191893 DOI: 10.1111/j.1523-5378.2009.00656.x]

12 **Choi HS**, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, Ryu HS. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. *World J Gastroenterol* 2012; **18**: 2377-2382 [PMID: 22654429 DOI: 10.3748/wjg.v18.i19.2377]

13 **Usta Y**, Saltik-Temizel IN, Demir H, Uslu N, Ozen H, Gurakan F, Yuce A. Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with Helicobacter pylori infection. *J Gastroenterol* 2008; **43**: 429-433 [PMID: 18600386 DOI: 10.1007/s00535-008-2187-4]

14 **Furuta T**, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. *Drug Metab Pharmacokinet* 2005; **20**: 153-167 [PMID: 15988117]

15 **Serrano D**, Torrado S, Torrado-Santiago S, Gisbert JP. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/- pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatments. *Curr Drug Metab* 2012; **13**: 1303-1312 [PMID: 22493986]

16 **Shimatani T**, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. *Clin Pharmacol Ther* 2006; **79**: 144-152 [PMID: 16413249]

17 **Klotz U**, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. *Basic Clin Pharmacol Toxicol* 2004; **95**: 2-8 [PMID: 15245569]

18 **Zhao F**, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z, Zhang G. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. *Helicobacter* 2008; **13**: 532-541 [PMID: 19166419 DOI: 10.1111/j.1523-5378.2008.00643.x]

19 **McNicholl AG**, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. *Aliment Pharmacol Ther* 2012; **36**: 414-425 [PMID: 22803691 DOI: 10.1111/j.1365-2036.2012.05211.x]

20 **Tang HL**, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. *PLoS One* 2013; **8**: e62162 [PMID: 23646118 DOI: 10.1371/journal.pone.0062162]

21 **Vítor JM**, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. *FEMS Immunol Med Microbiol* 2011; **63**: 153-164 [PMID: 22077218 DOI: 10.1111/j.1574-695X.2011.00865.x]

22 **Aiba Y**, Suzuki N, Kabir AM, Takagi A, Koga Y. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. *Am J Gastroenterol* 1998; **93**: 2097-2101 [PMID: 9820379]

23 **Pinchuk IV**, Bressollier P, Verneuil B, Fenet B, Sorokulova IB, Mégraud F, Urdaci MC. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. *Antimicrob Agents Chemother* 2001; **45**: 3156-3161 [PMID: 11600371]

24 **Tong JL**, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. *Aliment Pharmacol Ther* 2007; **25**: 155-168 [PMID: 17229240]

25 **Wang ZH**, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. *J Clin Gastroenterol* 2013; **47**: 25-32 [PMID: 23090045 DOI: 10.1097/MCG.0b013e318266f6c]

26 **Sachdeva A**, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2009; **29**: 720-730 [PMID: 19183156 DOI: doi: ]

27 **Zou J**, Dong J, Yu XF. Meta-analysis: the effect of supplementation with lactoferrin on eradication rates and adverse events during Helicobacter pylori eradication therapy. *Helicobacter* 2009; **14**: 119-127 [PMID: 19298339 DOI: 10.1111/j.1523-5378.2009.00666.x]

28 **Sachdeva A**, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. *Eur J Gastroenterol Hepatol* 2009; **21**: 45-53 [PMID: 19060631 DOI: 10.1097/MEG.0b013e32830d0eff]

29 **Zou J**, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. *Helicobacter* 2009; **14**: 97-107 [PMID: 19751434 DOI: 0.1111/j.1523-5378.2009.00716]

30 **Szajewska H**, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. *Aliment Pharmacol Ther* 2010; **32**: 1069-1079 [PMID: 21039671 DOI: 10.1111/j.1365-2036.2010.04457.x]

31 **Lionetti E**, Indrio F, Pavone L, Borrelli G, Cavallo L, Francavilla R. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. *Helicobacter* 2010; **15**: 79-87 [PMID: 20402810 DOI: 10.1111/j.1523-5378.2009.00743.x]

32 **Navarro-Rodriguez T**, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, Bogsan CS, Chinzon D, Eisig JN. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. *BMC Gastroenterol* 2013; **13**: 56 [PMID: 23530767 DOI: 10.1186/1471-230X-13-56]

33 **Mirzaee V**, Rezahosseini O. Randomized control trial: Comparison of Triple Therapy plus Probiotic Yogurt vs. Standard Triple Therapy on Helicobacter Pylori Eradication. *Iran Red Crescent Med J* 2012; **14**: 657-666 [PMID: 23285418]

34 **Medeiros JA**, Gonçalves TM, Boyanova L, Pereira MI, de Carvalho JN, Pereira AM, Cabrita AM. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. *Eur J Clin Microbiol Infect Dis* 2011; **30**: 555-559 [PMID: 21207091 DOI: 10.1007/s10096-010-1119-4]

35 **Prasertpetmanee S**, Mahachai V, Vilaichone RK. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. *Helicobacter* 2013; **18**: 270-273 [PMID: 23356886 DOI: 10.1111/hel.12041]

36 **Megraud F**, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. *Gut* 2013; **62**: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]

37 **Zullo A**, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C, Tomaselli G, Attili AF. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2000; **14**: 715-718 [PMID: 10848654]

38 **De Francesco V**, Zullo A, Hassan C, Faleo D, Ierardi E, Panella C, Morini S. Two new treatment regimens for Helicobacter pylori eradication: a randomised study. *Dig Liver Dis* 2001; **33**: 676-679 [PMID: 11785713]

39 **Vaira D**, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. *Ann Intern Med* 2007; **146**: 556-563 [PMID: 17438314]

40 **Zullo A**, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. *Gut* 2007; **56**: 1353-1357 [PMID: 17566020]

41 **Jafri NS**, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. *Ann Intern Med* 2008; **148**: 923-931 [PMID: 18490667]

42 **Tong JL**, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. *J Clin Pharm Ther* 2009; **34**: 41-53 [PMID: 19125902 DOI: 0.1111/j.1365-2710.2008.00969.x]

43 **Gatta L**, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. *Am J Gastroenterol* 2009; **104**: 3069-379; quiz 1080 [PMID: 19844205 DOI: 10.1038/ajg.2009.555]

44 **Chey WD**, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; **102**: 1808-1825 [PMID: 17608775]

45 **Malfertheiner P**, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007; **56**: 772-781 [PMID: 17170018]

46 **Fock KM**, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. *J Gastroenterol Hepatol* 2009; **24**: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]

47 **Gisbert JP**, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. *J Clin Gastroenterol* ; **44**: 313-325 [PMID: 20054285 DOI: 10.1097/MCG.0b013e3181c8a1a3]

48 **Greenberg ER**, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC, Meza-Montenegro MM, Peña R, Peña EM, Salazar-Martínez E, Correa P, Martínez ME, Valdivieso M, Goodman GE, Crowley JJ, Baker LH. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. *Lancet* 2011; **378**: 507-514 [PMID: 21777974 DOI: 10.1016/S0140-6736(11)60825-8]

49 **Horvath A**, Dziechciarz P, Szajewska H. Meta-analysis: sequential therapy for Helicobacter pylori eradication in children. *Aliment Pharmacol Ther* 2012; **36**: 534-541 [PMID: 22827718 DOI: 10.1111/j.1365-2036.2011.04665.x]

50 **Zullo A**, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. *Eur J Intern Med* 2013; **24**: 16-19 [PMID: 22877993 DOI: 10.1016/j.ejim.2012.07.006]

51 **Kate V**, Kalayarasan R, Ananthakrishnan N. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. *Drugs* 2013; **73**: 815-824 [PMID: 23625272 DOI: 10.1007/s40265-013-0053-z]

52 **Liou JM**, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC, Wu MS. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. *Lancet* 2013; **381**: 205-213 [PMID: 23158886 DOI: 10.1016/S0140-6736(12)61579-7]

53 **Gatta L**, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. *BMJ* 2013; **347**: f4587 [PMID: 23926315 DOI: 10.1136/bmj.f4587]

54 **Treiber G**, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. *Helicobacter* 1998; **3**: 54–58.

55 **Okada M**, Oki K, Shirotani T, Seo M, Okabe N, Maeda K, Nishimura H, Ohkuma K, Oda K. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. *J Gastroenterol* 1998; **33**: 640-645 [PMID: 9773927]

56 **Gisbert JP**, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. *Clin Exp Gastroenterol* 2012; **5**: 23-34 [PMID: 22457599 DOI: 10.2147/CEG.S25419]

57 **Kongchayanun C**, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. *Helicobacter* 2012; **17**: 282-285 [PMID: 22759328 DOI: 10.1111/j.1523-5378.2012.00953.x]

58 **Kim SY**, Lee SW, Hyun JJ, Jung SW, Koo JS, Yim HJ, Park JJ, Chun HJ, Choi JH. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. *J Clin Gastroenterol* 2013; **47**: 21-24 [PMID: 22647826 DOI: 10.1097/MCG.0b013e3182548ad4]

59 Sequential, Concomitant and Hybrid first-line therapies for H. pylori eradication: a prospective, randomized study. *J Med Microbiol* 2014; [PMID: 24586031 DOI: 10.1099/jmm.0.072322-0]

60 **Yanai A**, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. *World J Gastrointest Pharmacol Ther* 2012; **3**: 1-6 [PMID: 22408744 DOI: 10.4292/wjgpt.v3.i1.1]

61 **Wu DC**, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. *Clin Gastroenterol Hepatol* 2010; **8**: 36-41.e1 [PMID: 19804842 DOI: 10.1016/j.cgh.2009.09.030]

62 **Molina-Infante J**, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains. *Helicobacter* 2012; **17**: 269-276 [PMID: 22759326 DOI: 10.1111/j.1523-5378.2012.00947.x]

63 **Huang YK**, Wu MC, Wang SS, Kuo CH, Lee YC, Chang LL, Wang TH, Chen YH, Wang WM, Wu DC, Kuo FC. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. *J Dig Dis* 2012; **13**: 232-238 [PMID: 22435509 DOI: 10.1111/j.1751-2980.2012.00575.x]

64 **Georgopoulos S**, Papastergiou V, Xirouchakis E, Laudi F, Papantoniou N, Lisgos P, Spiliadi C, Fragou P, Skorda L, Karatapanis S. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. *Helicobacter* 2012; **17**: 49-53 [PMID: 22221616 DOI: 10.1111/j.1523-5378.2011.00911.x]

65 **McNicholl AG**, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. *Gut* 2014; **63**: 244-249 [PMID: 23665990]

66 **Georgopoulos SD**, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. *Helicobacter* 2013; **18**: 459-467 [PMID: 23714140 DOI: 10.1111/hel.12062]

67 **Molina-Infante J**, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. *Gastroenterology* 2013; **145**: 121-128.e1 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]

68 **Toros AB**, Ince AT, Kesici B, Saglam M, Polat Z, Uygun A. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. *Helicobacter* 2011; **16**: 225-228 [PMID: 21585608 DOI: 10.1111/j.1523-5378.2011.00823.x]

69 **Lim JH**, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. *Helicobacter* 2013; **18**: 180-186 [PMID: 23305083 DOI: 10.1111/j.1523-5378.2011.00823.x]

70 **Romano M**, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, Sica M, Rocco A, Salerno R, Marmo R, Federico A, Nardone G. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. *Gut* 2010; **59**: 1465-1470 [PMID: 20947881 DOI: 10.1136/gut.2010.215350]

71 **Georgopoulos SD**, Xirouchakis E, Mentis A. Is there a nonbismuth quadruple therapy that can reliably overcome bacterial resistance? *Gastroenterology* 2013; **145**: 1496-1497 [PMID: 24409502]

72 **Gisbert JP**, McNicoll A. Concomitant versus sequential non-bismuth quadruple regimens: systematic review and meta-analysis. *Gastroenterol Hepatol* 2014; in press.

73 **Hsu PI**, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. *Helicobacter* 2011; **16**: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]

74 **Sardarian H**, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. *Helicobacter* 2013; **18**: 129-134 [PMID: 23121338 DOI: 10.1111/hel.1201]

75 **Essa AS**, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. *Helicobacter* 2009; **14**: 109-118 [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671]

76 **Gisbert JP**, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. *Aliment Pharmacol Ther* 2011; **34**: 604-617 [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x]

77 **Shavakhi A**, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M, Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. *Helicobacter* 2013; **18**: 280-284 [PMID: 23433200 DOI: 10.1111/hel.12047]

78 **Manfredi M**, Bizzarri B, Sacchero RI, Maccari S, Calabrese L, Fabbian F, De'Angelis GL. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. *Helicobacter* 2012; **17**: 254-263 [PMID: 22759324 DOI: 10.1111/j.1523-5378.2012.00944.x]

79 **Sierra F**, Forero JD, Rey M, Botero ML, Cárdenas A. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2013; **37**: 1165-1171 [PMID: 23656465 DOI: 10.1111/apt.12329]

**P-Reviewers:** BalabanYH, Mansour-Ghanaei F, Paulssen EJ, Sari YS  **S-Editor:** Wen LL  **L-Editor:**  **E-Editor:**

**Thailand 2012**[57]

**Korea 2013**[58]

**Latin America 2011**[48]

**Turkey 2011**[68]

**Korea 2013**[69]

**Spain / Italy 2013**[67]

**Greece 2013**[66]

**Thailand 2012**[57]

**Spain 2013**[65]

**Greece 2011**[64]

**China 2012**[63]

**Spain 2012**[62]

**Taiwan 2010**[61]

**Japan 2012**[60]

**Italy** [59]

**Figure 1** **Intention-to-treat cure rates of concomitant therapy over the last three years in studies conducted in Latin America, Asia and Europe, broken down by the duration of therapy**. Studies with Intention-to-treat (ITT) < 85% are grey marked.

****

**Figure 2 Forest plot comparing sequential and concomitant therapy with a similar duration[72].**

**< 15%-20%**

**> 15%-20%**

**Metronidazole**

**resistance**

**Dual**

**resistance**

**Low**

**Clarithromycin resistance**

**14-day concomitant**

14-day hybrid1

14-day sequential1

14-day triple2

**High (>60%)**

**14-day bismuth**

14-day concomitant1

14-day triple2

**14-day concomitant**

**14-day bismuth**

14-day hybrid1

**14-day bismuth**

**< 15%**

**>15%**

**Figure 3 Regionalized therapeutic algorithm for *Helicobacter pylori* infection, based on clarithromycin and metronidazole resistance patterns.** 1Use conditioned to the rate of dual-resistant strains. Sequential, hybrid and concomitant therapies are expected to fail if the rate of dual clarithromycin- and metronidazole-resistant strains in > 5%, > 9% and >15%, respectively. 2Use if eradication rates > 90% have been documented.

**Table 1** **Impact of adding probiotics to eradication therapy (mostly standard triple therapy) on eradication rates and side effects, evaluated in six recent meta-analyses**

|  |  |  |  |
| --- | --- | --- | --- |
| **First author** **and year of publication** | **Probiotic strains** | **Eradication rates** | **Side effects** |
| **Tong *et al***[24]**, 2007****Wang *et al***[25]**, 2013** | ***Lactobacillus and bifidobacterium*** | Significantincrease | Significant Reduction |
| **Sachdeva *et al***[26]**, 2009****Zou *et al***[27]**, 2009** | **Lactoferrin** | SignificantIncrease | Significant Reduction/ No impact |
| **Sachdeva *et al***[28]**, 2009** | **Fermented milk** | SignificantIncrease | No impact |
| **Zou *et al***[29]**, 2009** |  ***Lactobacillus*** | SignificantIncrease | Significant reduction |
| **Szajewska *et al***[30]**, 2010** | ***Saccharomyces boulardii*** | Significantincrease | Significant reduction |

**Table 2 Updated systematic reviews and meta-analyses (2008-2012) in children and adults comparing triple and sequential therapy for** *Helicobacter pylori* **infection**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **First author** **and year of publication** | **Population and timeframe** | ***n*** | **Triple** **Therapy** **(95%CI)** | **Sequential** **therapy** **(95%CI)** | ***P value*** |
| **Horvath *et al***[49]**, 2012** | Children2005-2012 | 857 | 71% (66-75) | 78% (73-82) |  |
| **Zullo *et al***[50]**, 2013** | Adults andchildren2008-2012 | 2921 | 75.8% ( 73.5–78.1) | 80.6% (78.5–82.7) | 0.003 |
| **Kate *et al***[51]**, 2013** | Adults andchildren2008-2012 | 3247 | 71.4% (64-78) | 81.7% (78-85) | 0.02 |

**Table 3** E**fficacy of sequential and concomitant therapy, with a duration of 10 to 14 d, on dual clarithromycin-metronidazole resistant *Helicobacter pylori* strains**

|  |  |  |  |
| --- | --- | --- | --- |
| **First author, country, year of publication** | **Treatment duration (d)** | **Patients** | **Eradication rates** |
| **Concomitant therapy** |  |
| Wu *et al*[61], Thailand, 2010 | 10 | 4 | 3/4 (75%) |
| Molina-Infante *et al*[62], Spain, 2012 | 10 | 4 | 3/4 (75%) |
|  Huang *et al*[63], China, 2012 | 10 | 2 | 2/2 (100%) |
| Georgopoulos *et al*[66], Greece, 2013 | 10 | 10 | 7/10 (70%) |
| Molina-Infante *et al*[67], Spain-Italy, 2013 | 14 | 3 | 3/3 (100%) |
|  **Total**  | **23** | **18/23 (78%)** |
| **Sequential therapy** |  |
| Vaira *et al*[39], Italy, 2007 | 10 | 4 | 0/4 (0%) |
| Romano *et al*[70], Italy, 2010 | 10 | 3 | 0/3 (0%) |
| Wu *et al*[61], Thailand, 2010 | 10 | 3 | 1/3 (33%) |
| Molina-Infante *et al*[62], Spain, 2012 | 10 | 5 | 3/5 (60%) |
| Huang *et al*[63], China, 2012 | 10 | 4 | 2/4 (50%) |
| Liou *et al*[52], Taiwan, 2013 | 14 | 8 | 3/8 (37%) |
|  **Total**  | **27** | **9/27 (33%)** |

Adapted from Georgopoulos *et al*[71], with permission.